Effects of SGLT-2 inhibitors on renin-angiotensin-aldosterone system and their correlation with glucose metabolism in type 2 diabetes mellitus patients with hypertension: A prospective study.

ABSTRACT:

Background

The impact of sodium-glucose cotransporter-2 inhibitors (SGLT-2is), including dapagliflozin, on the renin-angiotensin-aldosterone system (RAAS) in type 2 diabetes mellitus (T2DM) patients remains controversial, as they may either activate or inhibit RAAS, subsequently influencing glucose metabolism and the accuracy of the aldosterone-to-renin ratio (ARR) in diagnosing primary aldosteronism (PA). However, the effects of SGLT-2is therapy on RAAS and their correlation with glucose metabolism have not been well studied.

Methods

A cohort of 147 patients with T2DM and hypertension was prospectively recruited and categorized into two groups: diabetic kidney disease group (DKD, n = 73) and non-DKD group (n = 74), based on diagnostic criteria for diabetic complications. Pa

SUBMITTER: Wang N 

PROVIDER: S-EPMC12626264 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature